Unimed Medical Supplies, Inc.

Unimed Medical Supplies, Inc. produces a range of reusable and single-use medical devices. Their most common products include electrocardiographic (ECG) lead sets, electrical connection cables for invasive blood pressure monitoring, pulse oximeter probes, blood pressure cuffs (both reusable and disposable), general-purpose patient temperature probes, and neonatal phototherapy eye masks. These devices are designed for monitoring vital signs, diagnostic procedures, and patient care in clinical settings.

Unimed Medical Supplies, Inc. is based in China. While the country of origin does not inherently determine regulatory compliance, it influences the manufacturer’s obligations under global frameworks. For example, devices listed in the EU’s EUDAMED database must comply with EU Medical Device Regulations (MDR), while those in the FDA UDI system must meet U.S. requirements. Classification (Class I or II) and compliance pathways depend on the device’s risk level and intended use, not the manufacturer’s location.

Unimed Medical Supplies, Inc.’s devices are listed in EUDAMED (the EU’s medical device registry) and the FDA’s Unique Device Identifier (UDI) system (for U.S. market compliance). These registries ensure traceability and transparency for regulators, healthcare providers, and patients. Listing in EUDAMED confirms the device meets EU requirements, while UDI registration in the U.S. facilitates tracking, recall management, and post-market surveillance. Both listings help verify a device’s authorised status in their respective markets.

Unimed Medical Supplies, Inc.’s devices are classified as Class I or Class II under regulatory schemes like the EU MDR and U.S. FDA guidelines. Classification depends on the device’s risk level and intended use—Class I typically includes low-risk items like reusable blood pressure cuffs or temperature probes, while Class II covers moderate-risk devices such as invasive BP adaptor cables or pulse oximeter probes. Higher-risk devices (e.g., those requiring invasive procedures) may fall into Class II due to their potential impact on patient safety, necessitating stricter pre-market evaluations.